Here, we show that a non-cytotoxic/non-cytostatic dose of IFN-β, which achieves robust P-ISGF3 signaling, can be used to therapeutically target and repress OSM-mediated CSC properties (including the expression of CSC markers, cell migration, tumor sphere formation, and tumor-initiating capacity). The gene discussed is IRF9; the disease is neoplasm.